Comparing the Efficacy and Safety of Induction Therapies for the Treatment of Patients with Proliferative Lupus Nephritis in South Africa

Table 4

Multivariable analysis for the predictors of remission and mortality.

	Remission		Mortality
	Odds ratio (95% CI)	value	Odds ratio (95% CI)	value
Age (years)	1.0 (0.9–1.1)	0.43	1.02 (0.94–1.09)	0.69
Gender
Female	1	0.48	1	0.66
Male	2.4 (0.2–28.3)		0.60 (0.06–5.87)
Ethnicity
Black Africans	1	0.62	1	0.59
Mixed ancestry	1.5 (0.3–6.5)		0.66 (0.14–3.01)
Induction regimen
IVCYC	1	0.20	1	0.11
MMF	3.2 (0.5–18.0)		0.07 (0.003–1.87)
Baseline eGFR	1.0 (0.97–1.0)	0.43	0.95 (0.92–0.98)	0.001
Baseline uPCR	1.0 (0.99–1.0)	0.26	0.99 (0.99–1.00)	0.15
Interstitial fibrosis	1.7 (0.4–6.7)	0.46	0.34 (0.09–1.24)	0.10
% crescents	3.0 (0.1–68.2)	0.49	0.83 (0.08–8.37)	0.87
% sclerosed glomeruli	0.5 (0.0–14.6)	0.69	0.99 (0.07–12.99)	0.99

IVCYC: intravenous cyclophosphamide, MMF: mycophenolate mofetil, eGFR: estimated glomerular rate; uPCR: urine protein-creatinine ratio.